What's New?

November 17, 2004
To read the archives, please click here.

In This Issue: Happenings Site News Meetings Chat Info

A Special Power Surge Guest Chat
Webcast from the Free Pituitary Symposium at NIH, October 29
Webcast ENDO 2004
Young Sam on Discovery Health show, "Mystery Diagnosis" Monday night, 2 future airings
Endocrine Society Urges NIH to Delay Public Access Plan
Olympic skater Scott Hamilton has a Pituitary Tumor
Growth Hormone Therapy May Reduce Morbidity, Mortality in Hypopituitary Adults
Next-Generation Growth Hormone
NIAID Launches Expanded Flu Web Site For The Media
NIAID Launches Influenza Genome Sequencing Project
High-Dose Steroids Up Heart Disease Risk Greatly
New Book Confronts Testosterone Issues
Upcoming Meetings in California and Florida; Local Meetings
Five new bios, one updated bio.
Read all about them below.

Next Online Newsletter will be Wednesday, November 24
read archived issues here »
Tomorrow, Nov. 18, 2004, 9 PM Eastern, in Power Surge!
Victor Davich Victor Davich has been a meditator for over 20 years. He has studied with some of America's foremost meditation teachers, including Shinzen Young and Sharon Salzberg.

Victor’s first book, The Best Guide to Meditation, was a Book of the Month Club Main Selection and is published worldwide. He has also been an attorney, screenwriter, and producer for Fortune 500 advertising agencies including Paramount Pictures.

Victor is the creator of 8 Minute Meditation: Quiet Your Mind. Change Your Life, the revolutionary new program that Time Magazine calls "The most American form of meditation yet." His program is contained in his just published book 8 Minute Meditation: Quiet Your Mind. Change Your Life. (Perigee) and his companion Guided Meditation CD, available at www.8minutes.org.

Victor will talk about 8 Minute Meditation and how meditation can empower us to approach any life transition or challenge with power, serenity, acceptance, and compassion for ourselves - and others.

*FREE* copies of 8 Minute Meditation will be given away at the chat.

Join Victor Davich, Nov. 18th, 9 PM Eastern. in Power Surge Live!
Your Cushing's Chatroom name and password should work in Power Surge, too!

Webcast from NIH Office of Research on Women's Health
Symposium on Family Hormonal Health

Webcast: NIH, Friday, October 29, 2004 Pituitary tumors are not rare and occur in nearly 20% of adults, worldwide. Although clinically significant, many of these tumors go undiagnosed for years. The abnormal hormone production caused by these tumors has severe and debilitating effects on growth, reproductive and sexual function, and neuroimmune function. Therefore, the purpose of this symposium is to increase awareness and scientific understanding of the all-encompassing nature of pituitary disorders in order to increase earlier diagnosis, disseminate knowledge of state of the art treatments, and pique interest in novel scientific study of the pathophysiology of these disorders and their many ramifications.

Speakers included:

  • Vivian W. Pinn, M.D.
  • Yvonne Maddox, Ph.D.
  • Captain Mohamed K. Shakir, M.D., F.A.C.P., F.R.C.P.
  • Ian McCutcheon, M.D.
  • Sylvia Asa, M.D., Ph.D.
  • George P. Chrousos, M.D.
  • Alan Rogol, M.D., Ph.D.
  • Phil Gold, M.D.
  • Sharmyn McGraw, Bram Levy and Robert Knutzen
  • Edward Oldfield, M.D.
  • Marc R. Blackman, M.D
  • James Segars, M.D.
  • Janet A. Schlecte, M.D.
  • Edward Laws, M.D., Ph.D.
  • Shereen Ezzat, M.D.

View this Webcast (7 hours, 21 minutes)

Webcast: ENDO 2004: from Controversies in the Treatment of Obesity to the differential diagnosis of Cushing's Syndrome or Thyroid Cancer, ENDO Webcast includes a diverse array of the clinical symposia presented at ENDO 2004.  This easy to view format includes slide graphics. This requires Real Player, avaliable free from http://www.real.com

Discovery Health aired Sam's show, "Mystery Diagnosis", Monday, November 15, 10PM EST. Upcoming viewings will be Nov. 19, 5AM EST and Nov. 21, 7PM EST, all on Discovery Health. More info here »

Endocrine Society Urges NIH to Delay Public Access Plan

CHEVY CHASE, Md., Nov. 12 /PRNewswire/ -- The Endocrine Society today asked the National Institutes of Health (NIH) to delay implementation of its plan to enhance public access to scientific research. While The Endocrine Society supports the concept of open access, it cannot support the NIH's proposal, as it raises several concerns and questions that must be addressed before any new policy can be applied.

In a letter sent to NIH Director Elias A. Zerhouni, M.D., The Endocrine Society shared several concerns regarding the NIH plan.

"We not only support free access to literature," writes Endocrine Society President Anthony Means, Ph.D., "we have invested our financial resources in developing and implementing definitive Web technology to accomplish this."

The Society currently makes all accepted manuscripts from its four peer- reviewed journals immediately available, without charge, to the public through its Web site. All of the Society's final published content also becomes available, free-of-charge, after 12 months.

The Endocrine Society's letter notes that the NIH plan duplicates existing resources; uses an untested publishing model; and leaves several unanswered questions regarding costs and measurements. The Society also conveys disappointment that in developing its plan for public access, the NIH failed to consult with established members of the scholarly publishing community, many of whom have advocated for NIH funding increases in recent years.

"The Endocrine Society is gravely concerned about the effect this wholesale shift in policy will have on the publishing models of the scholarly publishing community," notes the letter.

While the NIH calls for publicly funded scientific research to be freely available after six months, it has not shared the methodology and data used to establish this timeframe. A majority of journal publishers have determined that a 12-month free access policy is more sustainable than a six-month policy. The Endocrine Society also points out the NIH's failure to provide information about how it will assess the effectiveness of its policy and monitor its impact on stakeholders.

"We urge the NIH not to implement this proposal until sufficient data are collected to gauge the impact -- economic and otherwise -- of such a policy," said Dr. Means who offered to work with the NIH to revise their plan.

"We suggest there are other models that the NIH can use to promote open availability of scientific information and manage its research portfolio, and we would be happy to be part of a process to develop such models."

Founded in 1916, The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones, and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 11,000 scientists, physicians, educators, nurses and students in more than 80 countries. Together, these members represent all basic, applied, and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society, and the field of endocrinology, visit our web site at http://www.endo-society.org

SOURCE The Endocrine Society
CO: Endocrine Society; NIH; National Institutes of Health
ST: Maryland
Web site: http://www.endo-society.org
11/12/2004 10:22 EST

Discuss this topic. »

Olympic skater Scott Hamilton has a Pituitary Tumor
11/11/2004, 11:23 p.m. ET
The Associated Press

LOS ANGELES (AP) — World champion figure skater Scott Hamilton was diagnosed Thursday with a benign brain tumor, his publicist said.

Hamilton, 46, underwent a biopsy at The Cleveland Clinic in Ohio, and doctors expected to release him from the hospital by Friday.

Hamilton has a slow-growing, non-cancerous tumor in the region of the pituitary gland, said Dr. Gene Barnett, chairman of the clinic's brain tumor institute. Hamilton's publicist, Michael Sterling, said the skater has had vision problems in recent weeks.

"We will be working with him on a treatment plan moving forward," Barnett said.

Hamilton was diagnosed with testicular cancer in 1997 and treated with surgery and chemotherapy.

Hamilton, who lives in Los Angeles, is a four-time U.S. national champion, a four-time world champion and the 1984 Olympic gold medalist. He is now a skating show producer.

From http://www.cleveland.com/newsflash/national/index.ssf?/base/national-33/1100233751241850.xml&storylist=national

Discuss this topic. »

Growth Hormone Therapy May Reduce Morbidity, Mortality in Hypopituitary Adults

NEW YORK (Reuters Health) Aug 02 - In hypopituitary adults not treated with growth hormone (GH) replacement therapy, mortality rates are significantly increased compared with that of the normal population, according to a research project in Sweden. With GH replacement, however, overall mortality is not higher than normal.

Because of conflicting results in studies of patients with pituitary disease treated with GH, Dr. J. Svensson, at Sahlgrenska University Hospital in Goteborg, and colleagues compared outcomes of two cohorts of patients with those of the background population.

The first included 1411 hypopituitary adults (mean age at baseline 56.9 years) treated in-hospital between 1987 and 1992 who were followed until the end of 1994. During this period, the use of GH replacement therapy was not routinely used in Sweden.

Their risk ratio for death, compared with the general population, was 3.80 (p < 0.001). Death from cancer was increased nearly 4-fold as well (p < 0.001), with death due to cancer of the colon and rectum particularly high (risk ratio, 5.33, p < 0.001). The number of myocardial infarctions was increased (p < 0.01), as was the risk of cerebrovascular events (p < 0.001).

The second, prospective cohort study is ongoing, and includes 289 hypopituitary adult patients (mean age 47.6 years at baseline) being treated with GH replacement. This group did not differ significantly from the norm in mortality rates or in the rate of malignancies. The occurrence of myocardial infarctions was lower than would be expected (p < 0.05).

Although the two study cohorts are not fully comparable, "the present results could suggest that GH replacement therapy reduces mortality in hypopituitary adults," Dr. Svensson's group maintains.

There was an increased rate of cerebrovascular events even among those treated with GH therapy, the authors note, "demonstrating that factors other than GH in the overall treatment have an important effect on the outcome in this patient group."

J Clin Endocrinol Metab 2004;89:3306-3312

Serono and Nautilus Biotech Sign Worldwide Agreement to Develop and Commercialize a Next-Generation Growth Hormone

GENEVA, Switzerland and PARIS, France, November 15 /PRNewswire/ -- Serono (virt-x: SEO and NYSE: SRA) and protein evolution company Nautilus Biotech (Private) announced today that they have signed an agreement under which Serono and Nautilus will work together to develop the next-generation of human growth hormone, with improved biological, pharmacological and clinical profiles. This improved version of human growth hormone would allow less frequent injections of this therapeutic protein which is currently administered daily.

Under the terms of the agreement, Serono will receive an exclusive license to develop the next-generation human growth hormone and an exclusive option to license exclusive worldwide rights to develop, manufacture, and commercialize improved variants of the protein generated by Nautilus's rational evolution technology, a process mimicking natural evolution. In return, Nautilus will receive an initial fee and potential milestone payments related to development progress, regulatory submissions and approvals. If a new version of growth hormone is successfully developed and registered worldwide, and Serono exercises its option right, the aggregate amount of these payments could reach Euro 19 million. Nautilus will also receive undisclosed royalties on sales of the improved protein.

"Serono has a long-term commitment to people with endocrine and metabolic disorders requiring growth hormone treatment", said Tim Wells, Senior Executive VP Research of Serono. "We believe that the rational evolution technology of Nautilus represents a promising approach to generate growth hormone variants with great potential to deliver improved patient care."

"Serono has an impressive track record in the development and marketing of protein therapeutics," said Manuel Vega CEO of Nautilus Biotech. " We are confident that in Serono we have found a strong and committed partner to fully exploit the power of our protein improvement technology and to develop this new product as a competitive improvement to currently marketed alternatives. This agreement with Serono, a world leader in protein pharmaceuticals, validates our strategy and business model in the area of biopharmaceuticals".

Serono forward-looking statements

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Serono's current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2004. These factors include any failure or delay in Serono's ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, and government regulations limiting our ability to sell our products. Serono has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

About Serono

Serono is a global biotechnology leader. The Company has eight biotechnology products, Rebif(R), Gonal-F(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth and has recently entered the psoriasis area. The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas. Currently, there are approximately 30 ongoing development projects.

In 2003, Serono achieved worldwide revenues of US$2,018.6 million, and a net income of US$390.0 million, making it the third largest biotech company in the world. Its products are sold in over 90 countries. Bearer shares of Serono S.A., the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).

About Nautilus Biotech

Nautilus is focused on improving and developing next generation protein pharmaceuticals. Using its proprietary and unique technologies, Nautilus has generated a pipeline of improved therapeutic protein molecules with single amino acid substitutions; and has IP claims on 20 improved cytokines. Long lasting interferon alpha and interferon beta, presently in preclinical development, are Nautilus' lead molecules. Nautilus Biotech is a privately owned, VC backed company, founded in late 1999. More about Nautilus: www.nautilusbiotech.com

SOURCE Nautilus Biotech

CO: Nautilus Biotech

ST: France, Switzerland



11/15/2004 01:30 EST

Discuss this topic. »

U.S. Department of Health and Human Services


NIH News

National Institute of Allergy
and Infectious Diseases (NIAID)

Monday, November 15, 2004

Jennifer Wenger

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched its updated Web site on influenza research for members of the media and general public. Titled "Focus on the Flu," the Web site spotlights cutting-edge NIAID-supported research; graphics that

illuminate concepts important to understanding influenza research, such as reverse genetics and antigenic shift and drift; health-related facts sheets;

recent NIAID publications and Congressional testimony; and other flu resources.

The Web site is available at http://www.niaid.nih.gov/newsroom/FocusOn/Flu04.

NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov/.

U.S. Department of Health and Human Services


NIH News

National Institute of Allergy and Infectious Diseases (NIAID) http://www.niaid.nih.gov/

FOR IMMEDIATE RELEASE Monday, November 15, 2004

CONTACT: NIAID Press Office 301-402-1663 niaidnews@niaid.nih.gov


The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced a joint influenza genome sequencing project with several scientific partners. The project will help researchers understand how flu viruses evolve, spread and cause disease. According to its leaders, it has the potential to minimize the impact of annual flu outbreaks and to improve scientific knowledge of the emergence of pandemic flu viruses.

NIAID's collaborators include the National Center for Biotechnology Information (NCBI) of the NIH National Library of Medicine; the Centers for Disease Control and Prevention (CDC); St. Jude Children's Research Hospital in Memphis, TN; the Wadsworth Center of the New York State Department of Health in Troy, NY; the

Armed Forces Institute of Pathology in Washington, DC; and The Institute for

Genomic Research (TIGR) in Rockville, MD.

The sequencing effort, to be conducted in part by the NIAID Microbial Sequencing Center at TIGR, will reveal complete genetic blueprints of thousands of known human and avian influenza viruses. NIAID will rapidly make this sequence information publicly available through GenBank(r), an international, searchable online database funded by NIH, and the NIAID Bioinformatics Resource Center, a Web-accessible collection of genetic sequence information accompanied by data analysis tools.

"Influenza viruses present formidable scientific and public health challenges because they undergo continual genetic changes that enable them to evade the

body's immune response and sometimes become more virulent," says Anthony S. Fauci, M.D., director of NIAID. "This project not only provides a valuable resource for current influenza researchers, it also will attract investigators from other fields. We anticipate that these data will be used to recognize patterns of genetic changes and illuminate important questions such as how avian influenza viruses adapt to infect humans."

"Our goal is to provide scientists with the infrastructure they need to uncover potential targets for new vaccines, therapies and diagnostics against influenza," says Maria Y. Giovanni, Ph.D., who oversees the NIAID Microbial Sequencing Centers initiative. "Putting influenza sequence data in the public domain will help epidemiologists and other researchers improve their understanding of the overall molecular evolution of influenza viruses and the genetic factors that determine their virulence."

"This project is the influenza-virus equivalent of the human genome project," says Robert G. Webster, Ph.D., professor of virology at St. Jude Children's Research Hospital. St. Jude has a repository containing more than 12,000 avian influenza viruses collected over the past 27 years and will be the site for the sequencing of their genomes.

Despite annual vaccination programs, more than 200,000 people are hospitalized in the United States each year because of influenza, according to CDC. Influenza-related deaths average nearly 36,000 annually. Of increasing concern in Asia, avian influenza strains such as H5N1 continually mutate as they circulate among poultry, sometimes developing the ability to infect humans. Scientists are worried that such an avian virus could eventually mutate enough to be able to spread from person to person, resulting in a fast-moving, global pandemic.

David J. Lipman, M.D., director of NCBI, says that the whole genome sequence

data generated by the influenza genomics project will be important references for researchers who study how influenza viruses cause disease, conduct global surveillance of influenza activity, and assist in the selection of the most appropriate virus strains to include in the annual influenza vaccine. The sequence information will provide a larger and more representative sample for influenza than previously available to the public. The project will also enhance pandemic preparedness efforts by publishing genomic sequences of emerging avian influenza viruses, allowing scientists worldwide to analyze the strains and begin development of vaccines against them.

Dr. Giovanni notes that NIAID is working with collaborators who have well- defined collections of human and avian influenza viruses. "Their expertise will help us prioritize, select and obtain strains so we can offer a library of viral sequences that will be critically important to the scientific community."

The NIAID Microbial Sequencing Centers initiative funds the production of genome sequences that researchers can use to learn how an organism's genetic instructions drive it to cause disease. For more information on the Centers, visit http://www.niaid.nih.gov/dmid/genomes/mscs/default.htm.

NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.  News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

This NIH News Release is available online at: http://www.nih.gov/news/pr/nov2004/niaid-15.htm

High-Dose Steroids Up Heart Disease Risk Greatly

Mon Nov 15, 5:53 PM ET Health - Reuters

NEW YORK (Reuters Health) - Treatment with high doses of medicinal steroids (aka, glucocorticoids) more than doubles the risk of cardiovascular disease, new research suggests.

Many people have to take steroid drugs -- for example, by inhaler to treat asthma or in lotion form for skin allergies, while others need to take the drugs by injection or as pills to treat inflammatory condition like arthritis.

These agents are known to produce side effects, such as obesity, high blood pressure, and high blood sugar levels, which can lead to heart disease. Glucocorticoids given by injection or in oral form (termed systemic therapy) confer a higher risk of side effects, while non-systemic therapy using inhalers and lotions has a lower risk -- but the actual risk had not been quantified.

To investigate, Dr. Thomas M. MacDonald, from the Ninewells Hospital and Medical School in Dundee, Scotland, and colleagues compared cardiovascular events among 68,781 glucocorticoid users and for 82,202 non-users.

At the start of the study, none of the subjects had been hospitalized for heart disease or stroke. Over the study period a period, the rate of cardiovascular events in the glucocorticoid group was 23.9 per 1000 persons per year -- higher than the rate of 17.0 per 1000 per year seen in the non-user group.

For participants who took the highest doses of glucocorticoids, the rate was much higher -- 76.5 per 1000 persons per year, the researchers report in the Annals of Internal Medicine.

However, most of the danger was tied to systemic therapy. "Most patients exposed to glucocorticoids received only non-systemic glucocorticoids, and these prescriptions were not associated with a measurable increase in rates of cardiovascular disease," the team points out.

SOURCE: Annals of Internal Medicine, November 16, 2004.

From http://story.news.yahoo.com/news?tmpl=story&cid=594&e=9&u=/nm/20041115/hl_nm/heart_steroids_dc

Discuss this topic. »

New Book Confronts Testosterone Issues

Wellness Doctor Helps Men and Women Take Charge of Their Hormone Health

MONTEREY, Calif., Nov. 16 /PRNewswire/ -- More than 6 million U.S. men suffer from testosterone deficiency. It jeopardizes not only sexual and reproductive health, but also the cardiovascular system, bone and muscle strength, memory and emotional well-being. And increasingly, younger men are at risk.

What can men (and the women who love them) do to avoid this condition? And how can those who've been diagnosed improve their quality of life? Preventive medicine expert, Abraham Kryger, M.D., examines these issues in his groundbreaking new book, "Listen to Your Hormones, a Doctor's Guide to Sex, Love and Long Life".

According to Dr. Kryger, the key culprits are estrogen-like manmade chemicals that permeate our air, water and food supply.

"The link is undeniable," said Dr. Kryger. "I've seen first-hand how synthetic chemicals can disrupt endocrine and reproductive systems. They threaten our fertility, our intelligence -- our very survival. But there's help for those with low testosterone, and hope for others who want to minimize toxic exposure."

Based on current medical and environmental evidence, "Listen to Your Hormones" cuts through the hype and confusion about the vital role that testosterone plays in key bodily functions. It explains the consequences of ignoring hormone imbalances, and charts a course for men who must navigate the uncertain waters surrounding testosterone therapy.

More than a clinical analysis, the book reveals insights from real-world cases, and offers a blueprint for action. It suggests practical ways to assess, monitor, manage and improve male health. And it reinforces those ideas with extensive research.

Available immediately at a suggested retail price of U.S. $24.95, the book can be ordered online at www.sexloveandhormones.com or by phone at 831-373-4406. It is also in-stock at select bookstores. Digital versions of each chapter are expected to be available soon.

About the Author

Dr. Kryger is a wellness pioneer who has been at the forefront of research on hormones, nutrition and complementary medicine for 30 years. A board-certified family practitioner and preventive medicine specialist, Dr. Kryger heads a full-time private practice in Monterey. He has guided thousands of patients to optimal health by combining traditional medicine with the use of nutraceutical supplements and bioidentical hormones.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Abraham Kryger, MD, DMD http://www.profnet.com/ud-public.jsp?userid=500664

SOURCE Wellness MD Publications
CO: Wellness MD Publications
ST: California
Web site: http://www.wellnessmd.com
11/16/2004 05:00 EST

Discuss this topic. »

We welcome your articles, letters to the editor, bios and Cushing's information. Submit a Story or Article to either the snailmail CUSH Newsletter or to an upcoming email newsletter at

Newest Bios:
To add or edit your bio, please click here »
Dee Dee Dee Dee is not yet diagnosed. Minnesota
Jody E Jody's mother had Cushing's Syndrome with pheochromocytomas and had a bilateral adrenalectomy (BLA) in 1968. Jody has been diagnosed so far with bilateral multinodular adrenal hyperplasia. Tacoma, WA
Elizabeth Elizabeth was diagnosed with Rheumatoid Arthritis and was given regular cortisone injections. Several years later, she learned she had a pituitary tumor. In 1972, she had her adrenal glands removed. She was left with an egg-sized "empty sella where her huge pituitary tumor atrophied on its own. Wildwood, suburb of St. Louis, MO
Merlenna H Updated
Merlenna will have adrenal surgery Dec 1.
currently living in Dixon, California
but plans to move back to Hawaii
Michael B Michael B was first diagnosed with Cushing's in 1979 and had a bilateral adrenalectomy in 1980. In 1983 the symptoms reoccurred and he had a third adrenal removed in 1983. He then developed Nelson's syndrome and had his pituitary (plus tumour) removed, followed by another pituitary surgery then 5 weeks of radiotherapy. Leixlip, Co. Kildare, Ireland
Rochelle Rochelle had breast cancer before her Cushing's diagnosis. She has had her pituitary gland removed. Salt Lake City, UT

If you've been diagnosed with Cushing's, please participate in the Cushing's Register »

The information you provide will be used to create a register and will be shared with the medical world. It would not be used for other purposes without your expressed permission. Note: This information will not be sold or shared with other companies.

Lynne Clemens, Secretary of CUSH Org is be the person responsible for the creation of this register. If you have any questions you may contact her at lynnecush@comcast.net. You do not have to be a member of CUSH to fill out this questionnaire, as long as you are a Cushing’s patient. We do not believe that the world has an accurate accounting of Cushing’s patients. The only way to authenticate accuracy is with actual numbers. Your help will be appreciated. Thank you."


The Cushing's Store
for all kinds of Cushing's Labeled clothing, coffee mugs, totebags and much more. Great for your endo or Secret Someone.
Remember iGive.com...
... all year round.

iGive.com allows online stores to donate a percentage of their profit to running these Cushing's Support sites (the message boards at http://boards.cushings-interactive.com/invboard/, http://www.cushings-help.com, http://www.CUSH.org, http://www.cushings-support.com and http://www.cushingsonline.com) at no cost to you. So far, members have raised $317.75, and it hasn't cost them a cent.

See the list of over 470 participating merchants » When you register between now and the end of the year at http://www.iGive.com/cushings, you will earn an additional $5 for these Cushing's Support sites.

Thank you so much for your support.

CUSH can always use funds to help us all, by spreading the word and helping others. What can *you* do to help CUSH?

Upcoming Conventions, Meetings and Seminars:
December 4, 2004, UCLA Pituitary and Neuroendocrine Program and Harbor-UCLA Pituitary Center present a Second California Pituitary Conference in Beverly Hills, CA. More info and registration here »

January 28, 2005, Pituitary Update Conference For Patients And Physicians. More info here.

More upcoming local meetings are listed here »

Sign up for notification of local meetings. You need not be a CUSH member to participate.

Online Chats:
Please join us in the Chat Room TONIGHT at 9 PM Eastern.

The new chatroom is available through http://www.cushings-help.com/chatroom.htm. Since this is our own room, you won't need to go into another area after first logging in. You'll be right there!

The very first time you go in, you will have to register for this chat. Although you may use your user name and password from the message boards, you will still need to register those before being allowed into the room.

This room is always open, and has convenient links so that you can get needed information while you're chatting.

I hope to see you tonight!


Cushing's Help and Support at http://www.cushings-help.com
Cushing's Message Boards at http://boards.cushings-interactive.com/invboard/
Subscribe and Unsubscribe: Cushing's Newsletters and Chat Reminders http://www.cushings-help.com/aim.htm#reminder


Join us at:
E-mail: CushingsSupport@aol.com
Toll-Free: (877) 825-0128

On the Web: Cushing's Help Website
Cushing's Help and Support Web Boards
CUSH: Cushing's Understanding, Support and Help
©2000-2004 Cushing's Help and Support. All rights reserved.
Privacy Policy